Search Results 301-310 of 15267 for TNF
... TNF-α agents) within 2 weeks prior to initiation of study treatment or anticipation of need for systemic immunosuppressive medication during study treatment ...
Other immune mediating medications; for example, but not limited to, azathioprine, 6-mercaptopurine, cyclosporine, methotrexate, anti-TNF monoclonal ...
Received CD20 inhibitor, anti-tumor necrosis factor treatment, abatacept, alemtuzumab, any other experimental or biological therapy, intravenous ...
Immunomodulators; Tumor necrosis factor-alpha (TNFα) antagonists; Vedolizumab. Exclusion Criteria. Diagnosis of Crohn's disease or indeterminate colitis ...
... TNF-α antagonist or vedolizumab or ustekinumab, or having documented intolerance. Women of childbearing potential (WCBP) must have negative serum pregnancy ...
A Study to Evaluate the Effectiveness of a Dexamethasone Eluting Slim Modiolar Electrode in the Reduction of Fibrosis in a Newly Implanted Adult Population ...
... tumor necrosis factor [anti-TNF] agents) is allowed, provided the following is met: minimum of 2 weeks prior to Cycle 1, Day 1. Patients who have received ...
- Prior exposure to agents targeting the Tumor Necrosis Factor Receptor type 2 (TNFR2) receptor - Active autoimmune disease requiring systemic treatment in ...
... TNF-alpha agents) within 2 weeks prior to initiation of study treatment, or anticipation of need for systemic immunosuppressive medication during study ...
Histoplasmosis complicating tumor necrosis factor-alpha blocker therapy: a retrospective analysis of 98 cases. Clin Infect Dis. 2015 Aug 1; 61 (3):409-17 ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your gift to celebrate this day advances our doctors’ lifesaving work.